Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Ritter-Sovinz, P; Temming, P; Wackernagel, W; Tarmann, L; Langmann, G; Benesch, M; Lackner, H; Karastaneva, A; Schwinger, W; Seidel, M; Sperl, D; Strenger, V; Sorantin, E; Urban, C.
Retinoblastoma. Clinical symptoms, diagnostics and management
MONATSSCHR KINDERH. 2017; 165(9): 764-771. Doi: 10.1007/s00112-017-0364-3 [OPEN ACCESS]
Web of Science FullText FullText_MUG

 

Führende Autor*innen der Med Uni Graz
Ritter-Sovinz Petra
Co-Autor*innen der Med Uni Graz
Benesch Martin
Karastaneva Anna
Lackner Herwig
Langmann Gerald
Schwinger Wolfgang
Seidel Markus
Sorantin Erich
Sperl Daniela Ingrid
Strenger Volker
Urban Ernst-Christian
Vajda Lisa
Wackernagel Werner
Altmetrics:

Dimensions Citations:
Plum Analytics:


Scite (citation analytics):

Abstract:
Retinoblastoma is the most common malignant intraocular tumor in children. The most important initial symptoms are leukocoria and strabismus. As long as a retinoblastoma is diagnosed while it is still confined to the eye, survival is excellent in > 95% of children. Retinoblastoma may affect one or both eyes. The aim of treatment is to secure survival and especially for patients with bilateral disease, to retain as much vision as possible. A variety of eye-retaining treatment options are available, including systemic and local chemotherapy as well as focal ophthalmological treatment procedures (e.g. laser therapy, thermotherapy, cryotherapy and episcleral plaque brachytherapy). Almost 50% of affected children suffer from the heritable form of retinoblastoma that predisposes them to the development of further tumors outside the eye; they therefore require life-long follow-up. Treatment and follow-up are a multidisciplinary team effort.

Find related publications in this database (Keywords)
Leukocoria
Strabismus
Retinoblastoma
Neoplasms, second primary
Retinoblastoma-chemotherapy
© Med Uni Graz Impressum